Recent Company News

• 09:08 AM ET Nov 05, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:01 AM ET Nov 05, 2025
  

  Orexin program updates from Centessa Pharma leave room for debate

• 07:14 AM ET Nov 03, 2025
  

  Takeda Pharmaceutical completes 7-year pivotal phase 3Tetravalent Immunization against Dengue Efficacy Study trial evaluating its dengue vaccine QDENGA (¥4153.0000, 0)

• 08:36 AM ET Oct 30, 2025
  

  Transcript Intelligence: Takeda Pharmaceutical Q2 Earnings Themes (¥4257.0000, 0)

• 08:36 AM ET Oct 30, 2025
  

  Transcript Intelligence: Takeda Pharmaceutical Q2 Earnings Guidance (¥4257.0000, 0)

• 08:36 AM ET Oct 30, 2025
  

  Transcript Intelligence: Takeda Pharmaceutical Q2 Earnings Q&A (¥4257.0000, 0)

• 03:15 AM ET Oct 30, 2025
  

  StreetAccount Metrics Recap - Takeda Pharmaceutical Q2 Earnings (¥4257.0000, 0)

• 02:59 AM ET Oct 30, 2025
  

  Takeda Pharmaceutical reports Q2 net income attributable (¥11.8B) vs year-ago ¥92.0B (¥4257.0000, 0)

• 12:12 PM ET Oct 28, 2025
  

  StreetAccount Summary: U.S. unusual options volume

• 02:00 AM ET Oct 23, 2025
  

  Heidelberg Pharma's lead ADC candidate HDP-101 granted fast track designation by FDA for the treatment of multiple myeloma (€2.90, 0.00)